[关键词]
[摘要]
目的 观察补肺活血胶囊联合四联抗结核疗法治疗结核性胸膜炎的疗效。方法 选取2015年4月-2020年9月在新乡医学院第一附属医院诊治的96例结核性胸膜炎患者为研究对象,随机分为对照组(48例)和治疗组(48例)。对照组患者口服利福平片,0.6 g/次,1次/d;异烟肼片,0.3 g/次,1次/d;吡嗪酰胺片,1.25 g/次,1次/d;盐酸乙胺丁醇片,0.75 g/次,1次/d。治疗组在对照组的基础上口服补肺活血胶囊,4粒/次,3次/d。两组患者连续治疗6周。观察两组患者临床疗效,比较治疗前后两组患者胸水吸收时间、住院时间、临床症状缓解时间、胸膜厚度,炎症因子白介素-6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平及肺功能第1秒用力呼气容积(FEV1)和用力肺活量(FVC)。结果 治疗后,治疗组的总有效率明显高于对照组(91.67%vs 72.92%,P<0.05)。治疗后,治疗组的胸水吸收时间、住院时间、临床症状缓解时间明显短于对照组,胸膜厚度小于对照组(P<0.05)。治疗后,两组患者IL-6、CRP、TNF-α水平均较治疗前显著下降(P<0.05),且治疗组明显低于对照组(P<0.05)。治疗后,两组患者FEV1、FVC均较治疗前升高(P<0.05),且治疗组高于对照组(P<0.05)。结论 补肺活血胶囊联合四联抗结核疗法治疗结核性胸膜炎,可有效阻止疾病进展,缓解临床症状,促进肺功能改善,疗效可靠。
[Key word]
[Abstract]
Objective To observe the curative effect of Bufei Huoxue Capsules combined with quadruple anti-tuberculosis therapy in treatment of tuberculous pleurisy. Methods Patients (96 cases) with tuberculous pleurisy in the First Affiliated Hospital of Xinxiang Medical University from April 2015 to September 2020 were randomly divided into control (48 cases) and treatment (48 cases) groups. Patients in the control group were po administered with Rifampicin Tablets, Isoniazid Tablets, Pyrazinamide Tablets and Ethbambutoli Hydrochloridi Tablets, and they were respectively 0.6 g/time, 0.3 g/time, 1.25 g/time and 0.75 g/time, once daily. Patients in the treatment group were po administered with Bufei Huoxue Capsules, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, the pleural effusion absorption time, hospital stay, clinical symptom relief time, pleural thickness, the inflammatory factors levels of IL-6, CRP, and TNF-α, and the lung function indexes of FEV1 and FVC in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was significantly higher than that in the control group (91.67% vs 72.92%, P<0.05). After treatment, the pleural absorption time, hospital stay and clinical symptom relief time in the treatment group were significantly shorter than those in the control group (P<0.05), and the pleural thickness in the treatment group was less than that in the control group (P<0.05). After treatment, the levels of IL-6, CRP and TNF-α in two groups were significantly lower than those before treatment (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of FEV1 and FVC in two groups were higher than those before treatment (P<0.05), and which in the treatment group were higher than those in the control group (P<0.05). Conclusion Bufei Huoxue Capsules combined with quadruple anti-tuberculosis therapy in treatment of tuberculous pleurisy can effectively prevent the progression of the disease, alleviate clinical symptoms, promote the improvement of lung function, and the curative effect is reliable.
[中图分类号]
R974
[基金项目]
河南省医学科技攻关计划联合共建项目(2018020344)